Full Breakdown
HHS Push to Relax Controls on Unapproved Peptide Drugs Faces FDA Scientific Opposition
By Drooid · · How we work
In this breakdown
01
Policy Proposal to Ease Peptide Access
Health Secretary Robert F. Kennedy Jr. advanced a Department of Health and Human Services (HHS) plan that would direct the Food and Drug Administration (FDA) not to enforce existing rules against specialty pharmacies that compound a small group of injectable peptides—namely BPC-157, TB-500 and KPV. Under current FDA regulations, these substances are considered illegal drugs because they have not completed the agency’s safety and efficacy review. The proposal seeks to allow compounding pharmacies to sell the peptides without the usual enforcement actions.
02
FDA Scientific Staff Opposition
Most FDA scientific staff members voiced strong reservations, warning that the policy could undermine the agency’s long-standing mission to keep unproven health products off the market. Six insiders, speaking on condition of anonymity, said the staff had limited input in drafting the policy and that they “had major safety concerns” about deeming the peptides safe. In a July meeting, FDA staff reiterated that more than half a dozen of the peptides under consideration remain unproven regarding safety and effectiveness.
03
Compounding Industry Context
Compounding—customized drug preparation by pharmacies—has grown into a multibillion-dollar sector after a 2012 fungal meningitis outbreak linked to a Massachusetts compounding pharmacy heightened safety scrutiny. Historically, regulatory decisions for compounding have been the purview of the FDA, not HHS. The new HHS approach is unusual because federal law technically grants HHS authority over drug regulations, which it then delegates to the FDA.
04
Safety Measures Built into the HHS Plan
The HHS document incorporates several guardrails suggested by FDA staff. It requires pharmacies to source peptide ingredients from FDA-registered facilities, to verify chemical identity, and to collect side-effect information for safety analysis. In 2023, the FDA added more than a dozen peptides, including BPC-157 and TB-500, to a list of substances that should not be compounded because of risks such as allergic reactions, kidney damage and tumor growth.
05
Potential Implications
Kennedy argues that allowing compounding pharmacies to sell peptides will curb a “gray market” of imports from China and other countries, where many U.S. users obtain the products labeled “for research use only.” Critics contend that the policy could expose consumers to untested drugs and weaken enforcement precedent. The final impact will depend on how strictly the safety safeguards are applied and whether the FDA ultimately enforces or relaxes its existing compounding rules.